Theranexus: upbeat after partnership with Synerlab

(CercleFinance.com) - Theranexus shares gained over 6% on the Paris Bourse on Friday, following the announcement of a partnership with pharmaceutical subcontractor Synerlab to develop an oral solution for its pediatric treatment of Niemann-Pick type C disease.


Under the terms of the agreement, Synerlab will manufacture the first commercial batches of the proprietary pediatric formulation of miglustat developed by Theranexus for registration by the European Medicines Agency (EMA) in Niemann-Pick type C disease, with the aim of commercialization by 2026.

Theranexus - which patented and validated the oral formulation of miglustat in the context of its development in Batten disease - explains that this format presents a strong interest in the patient management of pediatric and/or dysphagic (swallowing disorders) patients.

Miglustat is currently the only treatment approved in Europe for the treatment of NPC, a severe neurodevelopmental disease affecting almost 1,500 patients in Europe, 71% of whom have a pediatric form.

The only formulation currently available is a 100 mg capsule, which is ill-suited to the treatment of this young patient population, given that 70% of them present significant swallowing disorders.

Copyright (c) 2024 CercleFinance.com. All rights reserved.